TIDMONT
RNS Number : 5965Q
Oxford Nanopore Technologies plc
19 October 2023
Oxford Nanopore Technologies plc
Mayo Clinic and Oxford Nanopore announce collaboration
19 October 2023
Mayo Clinic and Oxford Nanopore Technologies (LSE: ONT) (the
"Company" or "Oxford Nanopore") , the company delivering a new
generation of nanopore-based molecular sensing technology, today
unveiled a multi-year joint development collaboration to develop
new clinical tests for diseases and improve patient care.
Mayo Clinic and Oxford Nanopore have identified several areas of
development, spanning a wide breadth of applications from
translational research in human genetics to detection of genetic
predisposition to cancer.
"We are proud to work with Mayo Clinic to support the
development of new tests that will assist clinical decision-making
and improve patient lives. This collaboration shows that Oxford
Nanopore's technology is ready to support development and
validation of assays for clinical care, and it underscores our
maturity and long-term vision to transform this space. We have long
held the ambition to become a utility player in world-renowned,
global clinical centers of excellence, and this is our first step
toward achieving that vision," says Gordon Sanghera, CEO, Oxford
Nanopore Technologies.
Nanopore sequencing is well positioned to serve Mayo Clinic's
goals of improving testing in some of the hardest-to-characterise
conditions. The ability to sequence any-length fragments of DNA -
from short to long and ultra-long - and examine methylation in real
time offers the potential to provide clinicians with a more
complete picture of an evolving cancer genome quickly and
accurately. Methylation is particularly important, as this
typically requires bisulfite conversions and additional cost yet is
key to unmasking crucial insights.
"Pairing Oxford Nanopore's innovative nanopore sequencing with
Mayo Clinic's world-class clinical and diagnostic testing knowledge
further helps advance patient care," says Bobbi Pritt, M.D.,
interim chair of Mayo Clinic's Department of Laboratory Medicine
and Pathology. "We are excited to collaborate with Oxford Nanopore
on this effort to develop new clinical tests that will provide the
right answers for patients at the right time."
The collaboration activities will take place on Mayo Clinic's
campus in Rochester, Minnesota.
[ENDS]
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Company)
Tom Murray, Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
Mayo Clinic Media Contact: Suzanne Ferguson,
ferguson.suzanne1@mayo.edu
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation
in clinical practice, education, and research, and to providing
compassion, expertise, and answers to everyone who needs healing.
Visit Mayo Clinic News Network for additional Mayo Clinic news.
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology that is currently used for
real-time, high-performance, accessible, and scalable analysis of
DNA and RNA. The technology is used in more than 120 countries, to
understand the biology of humans, plants, animals, bacteria,
viruses and environments as well as to understand diseases such as
cancer. Oxford Nanopore's technology also has the potential to
provide broad, high impact, rapid insights in a number of areas
including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements.
For example, statements regarding expected revenue growth and
profit margins are forward-looking statements. Phrases such as
"aim", "plan", "expect", "intend", "anticipate", "believe",
"estimate", "target", and similar expressions of a future or
forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future
business and financial performance and financial condition, and by
definition address matters that are, to different degrees,
uncertain. Our results could be affected by macroeconomic
conditions, the COVID-19 pandemic, delays in our receipt of
components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products
or accelerated adoption of pathogen surveillance. These or other
uncertainties may cause our actual future results to be materially
different than those expressed in our forward-looking
statements.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGREKLBFXBLZFBE
(END) Dow Jones Newswires
October 19, 2023 02:00 ET (06:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Nanopore Technolo... (LSE:ONT)
Historical Stock Chart
From Apr 2023 to Apr 2024
